The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

The EAP trial, funded by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) 1-3, will evaluate the safety and efficacy of MN-166 in approximately 200 ALS patients. Dr.

Ten principal investigators (PIs) fired from the National Institute of Neurological Disorders and Stroke (NINDS) were called back to work and told a "computer error" or "coding error" led to ...

Stroke adjudication committee for CREST 2 trial and executive committee for DEFUSE 3 trial (National Institute of Neurological Disorders and Stroke) ...